Last reviewed · How we verify

infliximab therapeutic drug monitoring

Imelda GI Clinical Research Center · FDA-approved active Biologic

infliximab therapeutic drug monitoring is a TNF-α inhibitor (monoclonal antibody) Biologic drug developed by Imelda GI Clinical Research Center. It is currently FDA-approved for Crohn's disease, Ulcerative colitis, Rheumatoid arthritis.

Infliximab is a chimeric monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.

Infliximab is a chimeric monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. Used for Crohn's disease, Ulcerative colitis, Rheumatoid arthritis.

At a glance

Generic nameinfliximab therapeutic drug monitoring
SponsorImelda GI Clinical Research Center
Drug classTNF-α inhibitor (monoclonal antibody)
TargetTNF-α (tumor necrosis factor-alpha)
ModalityBiologic
Therapeutic areaImmunology / Gastroenterology
PhaseFDA-approved

Mechanism of action

Infliximab blocks TNF-α signaling by binding directly to soluble and membrane-bound TNF-α, preventing its interaction with TNF receptors on immune cells and reducing inflammatory responses. This therapeutic drug monitoring service measures infliximab serum concentrations and anti-drug antibodies to optimize dosing and predict treatment response or loss of efficacy in patients with inflammatory bowel disease and other TNF-α-mediated conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about infliximab therapeutic drug monitoring

What is infliximab therapeutic drug monitoring?

infliximab therapeutic drug monitoring is a TNF-α inhibitor (monoclonal antibody) drug developed by Imelda GI Clinical Research Center, indicated for Crohn's disease, Ulcerative colitis, Rheumatoid arthritis.

How does infliximab therapeutic drug monitoring work?

Infliximab is a chimeric monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.

What is infliximab therapeutic drug monitoring used for?

infliximab therapeutic drug monitoring is indicated for Crohn's disease, Ulcerative colitis, Rheumatoid arthritis, Ankylosing spondylitis, Psoriasis.

Who makes infliximab therapeutic drug monitoring?

infliximab therapeutic drug monitoring is developed and marketed by Imelda GI Clinical Research Center (see full Imelda GI Clinical Research Center pipeline at /company/imelda-gi-clinical-research-center).

What drug class is infliximab therapeutic drug monitoring in?

infliximab therapeutic drug monitoring belongs to the TNF-α inhibitor (monoclonal antibody) class. See all TNF-α inhibitor (monoclonal antibody) drugs at /class/tnf-inhibitor-monoclonal-antibody.

What development phase is infliximab therapeutic drug monitoring in?

infliximab therapeutic drug monitoring is FDA-approved (marketed).

What are the side effects of infliximab therapeutic drug monitoring?

Common side effects of infliximab therapeutic drug monitoring include Infections (including tuberculosis, fungal, and opportunistic), Infusion reactions, Headache, Abdominal pain, Nausea, Antibody formation (anti-infliximab antibodies).

What does infliximab therapeutic drug monitoring target?

infliximab therapeutic drug monitoring targets TNF-α (tumor necrosis factor-alpha) and is a TNF-α inhibitor (monoclonal antibody).

Related